Topline results from our second Phase 3 study, Study 502, are anticipated late in the second quarter of this year. Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
Intra-Cellular Reports Phase 3 Topline Results From Study 501 Evaluating Lumateperone As Adjunctive Therapy In Patients With Major Depressive Disorder; Lumateperone 42 Mg Met The Primary Endpoint
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.